Stockscreener 앱 받기
6.02
3.08%
0.18
시장 영업 전:
6.01
-0.010
-0.17%
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Options Data Show Bullish Bias in Candel Therapeutics Inc.High Conviction Intraday Stock Signals Detected - beatles.ru
How does Candel Therapeutics Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
What is Candel Therapeutics Inc. company’s growth strategyExceptional market positioning - Jammu Links News
Will Candel Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTechnical Breakout List - metal.it
What is the dividend policy of Candel Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are the technical indicators suggesting about Candel Therapeutics Inc.Massive profits - jammulinksnews.com
What drives Candel Therapeutics Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Candel Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Is Candel Therapeutics Inc. a good long term investmentExplosive returns - PrintWeekIndia
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics Gets European Orphan Status for Pancreatic Cancer Drug CAN-2409 - citybiz
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive Investors
Revolutionary Pancreatic Cancer Treatment Shows 31.4-Month Survival, Secures Critical EU Designation - Stock Titan
Candel Therapeutics: Promising Phase 3 Data and Secured Financial Runway Justifies Buy Rating - AInvest
0.24%
3.39%
자본화:
|
볼륨(24시간):